January 31, 2019 06:40 AM EST
Pharma

FDA bless­es Mer­ck’s PhI­II ef­fort to top­ple a mega-block­buster — but there’s al­so a lit­tle biotech in this game

John Carroll

Editor & Founder

Mer­ck just got a leg up in its quest to leapfrog Pfiz­er’s best-sell­ing pneu­mo­coc­cal con­ju­gate vac­cine Pre­vnar 13. The FDA is pro­vid­ing its

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Chron­ic care start­up Oma­da Health files to go pub­lic

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times